Vor BioPharma Inc (VOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.12+1.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · VOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -13.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
VOR — director transition
Dated 2026-07-07
Director — Andrew Levin, M.D., Ph.D.: Dr. Andrew Levin resigned as a Director of Vor Biopharma Inc.
Why it matters: Vor Bio remains loss-making, with a reported $62.8 million net loss in 2026-Q2. A larger loss could add pressure to its cash runway.
Worry ifThe November 12 report shows a net loss above $62.8 million for the quarter.
Less concerning ifThe November 12 report shows a net loss below $62.8 million, or reports a net profit.
Why it matters: China's approval adds evidence for telitacicept in IgAN. Vor Bio has rights outside Greater China, but the release gives no global IgAN trial plan.
Watch forVor Bio names a trial, start date, or filing plan for telitacicept in IgAN outside Greater China.
Also watch forVor Bio says it will not pursue IgAN outside Greater China, or gives no IgAN plan in its next update.
Why it matters: Management reported $450 million in cash runway into mid-2028. New cash or spending details can show whether that runway still holds.
Watch forOn November 12, Vor Bio confirms cash runway into mid-2028 or extends it.
Also watch forOn November 12, Vor Bio cuts its runway estimate or reports cash below the level needed to reach mid-2028.
Why it matters: Positive trial results could support approval outside China. Delays or weak results would hurt that case.
Watch forA company update reports that the global Phase 3 gMG or SjD trial met its main goal.
Also watch forThe company reports a missed main trial goal or pushes a planned trial update back.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $902 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,719 loss on $10,000 · 67.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.